These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30642238)

  • 21. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 22. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia.
    Sullivan DR; Hamilton-Craig I; van Bockxmeer F; Watts GF;
    Heart Lung Circ; 2012 Mar; 21(3):159-62. PubMed ID: 22364837
    [No Abstract]   [Full Text] [Related]  

  • 23. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
    Karayan L; Qiu S; Betard C; Dufour R; Roederer G; Minnich A; Davignon J; Genest J
    Arterioscler Thromb; 1994 Aug; 14(8):1258-63. PubMed ID: 8049186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial Hypercholesterolaemia in the Era of Genetic Testing.
    Hughes DP; Viljoen A; Wierzbicki AS
    Curr Cardiol Rep; 2016 May; 18(5):42. PubMed ID: 27002618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.
    Raal FJ; Pappu AS; Illingworth DR; Pilcher GJ; Marais AD; Firth JC; Kotze MJ; Heinonen TM; Black DM
    Atherosclerosis; 2000 Jun; 150(2):421-8. PubMed ID: 10856535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.
    Kajinami K; Yagi K; Higashikata T; Inazu A; Koizumi J; Mabuchi H
    Am J Cardiol; 1998 Jul; 82(1):113-7. PubMed ID: 9671018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia.
    Vohl MC; Szots F; Lelièvre M; Lupien PJ; Bergeron J; Gagné C; Couture P
    Atherosclerosis; 2002 Feb; 160(2):361-8. PubMed ID: 11849659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Familial hypercholesterolemia].
    Kajinami K; Mabuchi H
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):67-72. PubMed ID: 9645010
    [No Abstract]   [Full Text] [Related]  

  • 29. Heterozygous familial hypercholesterolemia case study.
    Friedrich DA
    J Am Acad Nurse Pract; 2010 Oct; 22(10):523-6. PubMed ID: 21040085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
    Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial hypercholesterolaemia in Australia: new insights and developments.
    Hamilton-Craig IR; Watts GF
    Med J Aust; 2013 Feb; 198(2):72-3. PubMed ID: 23373481
    [No Abstract]   [Full Text] [Related]  

  • 32. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
    Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
    Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
    Tikkanen MJ; Helve E; Nikkilä EA
    Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excess Aortic Pathology Risk in Patients with Genetically Verified Familial Hypercholesterolaemia: A Prospective Norwegian Registry Study.
    Mundal LJ; Igland J; Leren TP; Retterstøl K
    Eur J Vasc Endovasc Surg; 2021 Apr; 61(4):712-713. PubMed ID: 33485759
    [No Abstract]   [Full Text] [Related]  

  • 36. Statins and familial hypercholesterolaemia.
    Neil A; Humphries SE
    BMJ; 2009 Jan; 338():a3041. PubMed ID: 19158168
    [No Abstract]   [Full Text] [Related]  

  • 37. Homozygous familial hypercholesterolaemia.
    Gagné C; Moorjani S; Torres AL; Brun D; Lupien PJ
    Lancet; 1994 Jan; 343(8890):177. PubMed ID: 7904025
    [No Abstract]   [Full Text] [Related]  

  • 38. The Power to Predict: Does LDLR Mutation Status Determine Statin Responsiveness?
    Berberich AJ
    Can J Cardiol; 2022 Mar; 38(3):293-296. PubMed ID: 35032620
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
    Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular genetics of familial hypercholesterolaemia in Norway.
    Leren TP; Tonstad S; Gundersen KE; Bakken KS; Rødningen OK; Sundvold H; Ose L; Berg K
    J Intern Med; 1997 Mar; 241(3):185-94. PubMed ID: 9104431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.